Two National Guard members shot near White House
Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences NASDAQ:PLSE, a $1.2 billion market cap biotech company, sold 20,400 shares of common stock on September 18 and 19, 2025, for approximately $377,191. According to InvestingPro data, the stock has shown significant volatility with a beta of 1.68. The sales were executed at a weighted average price ranging from $18.48 to $19.48 per share.
On the same dates, Danahy exercised options to acquire 20,400 shares of Pulse Biosciences stock at an exercise price of $1.53, for a total value of $31,212.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. Following these transactions, Danahy directly owns 43,298 shares of Pulse Biosciences.
In other recent news, Pulse Biosciences reported its Q2 2025 earnings, highlighting a significant increase in costs and expenses, which resulted in a widened net loss compared to the previous year. Despite these financial challenges, the company’s cash reserves remain strong. Additionally, the U.S. Food and Drug Administration has approved Pulse Biosciences’ Investigational Device Exemption application for the NANOCLAMP AF study. This study will evaluate the company’s nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery System for treating atrial fibrillation and will enroll up to 136 patients across 20 sites. Moreover, a first-in-human clinical feasibility study demonstrated the effectiveness of the nsPFA technology for treating benign thyroid nodules, with significant reductions in nodule size reported. This study was conducted at Ospedale del Mare in Naples, Italy, and published in the Journal Thyroid. These developments reflect the company’s ongoing efforts to advance its medical technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.